News | Quality Assurance (QA) | June 07, 2019

IBA Dosimetry Launches myQA iON

Quality assurance software will shorten patient QA time by a factor of three by integrating log file QA, Monte Carlo calculation and workflow streamlining

IBA Dosimetry Launches myQA iON

June 7, 2019 — IBA (Ion Beam Applications S.A.) announced the launch of myQA iON at the 2019 Particle Therapy Co-Operative Group (PTCOG) conference, June 10-15 in Manchester, U.K. The company said myQA iON significantly reduces the time needed for patient quality assurance (QA) for proton therapy (PT).

The use of PT machine log files, process automation, task-based workflows and the latest web technologies in myQA iON significantly increase QA efficiency while ensuring patient treatment safety. Compared to conventional detector measurements (at isocenter), myQA iON enables a reduction of the QA measurement effort that results in a three times faster patient QA. This efficiency increase was confirmed by a global survey conducted amongst 37 practicing medical physicists at proton therapy centers.

“Combining irradiation logs and an independent dose recalculation with myQA iON, we intend to reduce the amount of measurements performed for patient QA by approximately 90 percent,” said Stefan Both, professor and head of medical physics at the Department of Radiation Oncology, University Medical Center Groningen, Netherlands.

myQA iON combines the analysis of irradiation log files and sophisticated high-accuracy Monte Carlo dose recalculation to provide the user with an independent QA dose calculation, as well as the ability to verify the quality and safety of each patient treatment fraction.

“The ability to automate our patient QA, and the flexibility to use irradiation log files, real dose measurements and Monte Carlo secondary recalculations in one system will bring us to a new level in PT treatment plan QA efficiency and accuracy,” said Zuofeng Li, physics director at the University of Florida Health Proton Therapy Institute, Jacksonville, Fla.

The software environment offers all patient QA tasks and workflow steps in a single interface. The latest web technologies allow users to access their patient QA anytime and anywhere within the hospital network. myQA iON supports patient QA for proton therapy machines of all major vendors.

myQA iON is currently undergoing U.S. Food and Drug Administration (FDA) 510(k) review.

For more information: www.iba-worldwide.com

Related Content

Radiotherapy has been used to treat cancers for more than a century and continues to be utilized in cancer treatment plans today. Since the introduction of radiotherapy, clinicians have been working tirelessly to further refine treatments to better target cancer.
Feature | Radiation Therapy | July 06, 2020 | By Yves Archambault
Everything has room for improvement, right? Right. When it comes to cancer care, it is no different.
Proton therapy has evolved, and future predictions include smaller systems, more sophisticated proton dosimetry and devices that manipulate the proton beam
Feature | Proton Therapy | July 06, 2020 | By Minesh Mehta, M.D.
The field of proton...
Researchers reviewed results of prostate biopsies on over 3,400 men who had targets identified on prostate MRI and found that the positive predictive value of the test for prostate cancer was highly variable at different sites
News | Prostate Cancer | July 01, 2020
July 1, 2020 — Prostate MRI is an emerging technology used to identify and guide treatment for...
Cardiac MR can offer data above and beyond anatomical imaging, which is the main reason why this system was installed at Baylor Scott White Heart Hospital in Dallas. The system is a dedicated heart MRI scanner.

Cardiac MR can offer data above and beyond anatomical imaging, which is the main reason why this system was installed at Baylor Scott White Heart Hospital in Dallas. The system is a dedicated heart MRI scanner.

News | Pediatric Imaging | June 29, 2020
June 29, 2020 — A type of smart magnetic r...
Case abstraction study period was from 10 March to 7 April 2020. Follow-up of abstracted cases was until 7 May 2020.

Case abstraction study period was from 10 March to 7 April 2020. Follow-up of abstracted cases was until 7 May 2020. Courtesy of Nature Medicine

News | Coronavirus (COVID-19) | June 25, 2020
June 25, 2020 — The characterization of COVID-19
Stephen M. Hahn, M.D., Commissioner of Food and Drugs - Food and Drug Administration

Stephen M. Hahn, M.D., Commissioner of Food and Drugs - Food and Drug Administration

News | Coronavirus (COVID-19) | June 23, 2020
June 23, 2020 — On June 23, 2020, ...
The Global Contrast Injectors Market will grow by $613.47M during 2020-2024, according to Technavio
News | Contrast Media Injectors | June 17, 2020
June 17, 2020 — Technavio has been monitoring the ...